We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
+46.01%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$648M
AUM Growth
+$140M
Cap. Flow
+$12.9M
Cap. Flow %
1.99%
Top 10 Hldgs %
69.93%
Holding
36
New
9
Increased
7
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
GOSS icon
Gossamer Bio
GOSS
+$21.7M
2
TCDA
Tricida, Inc. Common Stock
TCDA
+$21M
3
PLRX icon
Pliant Therapeutics
PLRX
+$20.7M
4
MIST icon
Milestone Pharmaceuticals
MIST
+$18.4M
5
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$13.9M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$41.5M
2
CLDX icon
Celldex Therapeutics
CLDX
+$24.2M
3
RLMD icon
Relmada Therapeutics
RLMD
+$20.8M
4
VTGN icon
VistaGen Therapeutics
VTGN
+$18.2M
5
WHWK
Whitehawk Therapeutics
WHWK
+$14.5M

Sector Composition

Rank Sector Weight
1 Healthcare 96.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LYRA
26
DELISTED
LYRA THERAPEUTICS INC
LYRA
$4.63M 0.71%
18,483
– –
IMCR icon
27
Immunocore
IMCR
$1.72B
$4.44M 0.69%
+94,605
New +$4.51M
ATYR
28
aTyr Pharma
ATYR
$47.6M
$4.2M 0.65%
1,398,889
– –
RLYB icon
29
Rallybio
RLYB
$84.5M
$3.89M 0.6%
33,567
– –
AFMD
30
DELISTED
Affimed
AFMD
$2.94M 0.45%
142,857
– –
CLDX icon
31
Celldex Therapeutics
CLDX
$2.99B
$2.11M 0.33%
75,000
-790,116
-91% -$24.2M
TVTX icon
32
Travere Therapeutics
TVTX
$5.2B
– –
-1,711,102
Closed -$41.5M
VTGN icon
33
VistaGen Therapeutics
VTGN
$9.89M
– –
-689,910
Closed -$18.2M
XENE icon
34
Xenon Pharmaceuticals
XENE
$6.06B
– –
-30,000
Closed -$913K
WHWK
35
Whitehawk Therapeutics
WHWK
$190M
– –
-1,173,518
Closed -$14.5M
KDNY
36
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-489,618
Closed -$8.56M
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q3 2022 Portfolio in Review

As of Q3 2022, VR Adviser held 36 positions worth $648M, up 28% from $508M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

VR Adviser's Q3 2022 filing shows 9 new, 7 increased, 3 reduced and 5 closed positions. Its largest new stake was Gossamer Bio: 1,747,000 shares worth $20.9M. The largest sale was Travere Therapeutics, an estimated $41.5M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier.

  • VR Adviser's largest Q3 2022 buy was Gossamer Bio: 1,747,000 shares worth $20.9M.
  • VR Adviser added most to Tricida, Inc. Common Stock in Q3 2022, an estimated $21M increase.
  • VR Adviser's biggest Q3 2022 reduction was Celldex Therapeutics, cutting an estimated $24.2M.
  • VR Adviser fully exited Travere Therapeutics in Q3 2022, selling an estimated $41.5M.
  • VR Adviser's ten largest holdings make up 70% of its $648M portfolio in Q3 2022.
  • VR Adviser opened 9 new positions and closed 5 in Q3 2022.
  • VR Adviser's portfolio value rose 28% quarter-over-quarter to $648M.

Based on VR Adviser's 13F filing for Q3 2022, filed 14 Nov 2022.